JP2023542950A5 - - Google Patents
Info
- Publication number
- JP2023542950A5 JP2023542950A5 JP2023518378A JP2023518378A JP2023542950A5 JP 2023542950 A5 JP2023542950 A5 JP 2023542950A5 JP 2023518378 A JP2023518378 A JP 2023518378A JP 2023518378 A JP2023518378 A JP 2023518378A JP 2023542950 A5 JP2023542950 A5 JP 2023542950A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- sequence
- aav
- item
- aav vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063082208P | 2020-09-23 | 2020-09-23 | |
| US63/082,208 | 2020-09-23 | ||
| PCT/US2021/051758 WO2022066911A1 (en) | 2020-09-23 | 2021-09-23 | Compositions and methods for inhibiting alpha-synuclein aggregation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023542950A JP2023542950A (ja) | 2023-10-12 |
| JP2023542950A5 true JP2023542950A5 (enExample) | 2024-10-02 |
Family
ID=80845817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518378A Pending JP2023542950A (ja) | 2020-09-23 | 2021-09-23 | α－シヌクレインの凝集を阻害するための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240025953A1 (enExample) |
| EP (1) | EP4216978A4 (enExample) |
| JP (1) | JP2023542950A (enExample) |
| CN (1) | CN116457466A (enExample) |
| AU (1) | AU2021349261A1 (enExample) |
| CA (1) | CA3192936A1 (enExample) |
| WO (1) | WO2022066911A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024229777A1 (zh) * | 2023-05-11 | 2024-11-14 | 深圳先进技术研究院 | 一种aav载体及其应用 |
| CN116590342B (zh) * | 2023-05-11 | 2026-04-03 | 普递瑞(上海)医药有限公司 | 一种aav载体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1680145A4 (en) * | 2003-10-14 | 2007-05-23 | Neurologix Res Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES |
| EP2154969B1 (en) * | 2007-05-16 | 2015-11-18 | The Brigham and Women's Hospital, Inc. | Treatment of synucleinopathies |
| AU2013337354A1 (en) * | 2012-11-05 | 2015-05-21 | Genzyme Corporation | Compositions and methods for treating proteinopathies |
| US20170184612A1 (en) * | 2014-04-09 | 2017-06-29 | The Trustees Of Columbia University In The City Of New York | Use of leukocytes and novel biomarkers in the diagnosis, confirmation, and treatment of a neurological disorder |
| KR102423442B1 (ko) * | 2015-12-11 | 2022-07-20 | 캘리포니아 인스티튜트 오브 테크놀로지 | 아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드 |
| US10815271B2 (en) * | 2016-06-29 | 2020-10-27 | The Regents Of The University Of California | Structure-based peptide inhibitors of alpha-synuclein aggregation |
| EP3668485A1 (en) * | 2017-08-18 | 2020-06-24 | The Medical College of Wisconsin, Inc. | Srcp1-based therapy for diseases associated with protein aggregation |
| WO2019068854A1 (en) * | 2017-10-06 | 2019-04-11 | Ospedale San Raffaele S.R.L. | GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS |
| MX2020011386A (es) * | 2018-04-27 | 2021-01-29 | Spacecraft Seven Llc | Terapia genica para la degeneracion del snc. |
| CA3118692A1 (en) * | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Cell-based gene therapy for neurodegenerative diseases |
-
2021
- 2021-09-23 WO PCT/US2021/051758 patent/WO2022066911A1/en not_active Ceased
- 2021-09-23 AU AU2021349261A patent/AU2021349261A1/en active Pending
- 2021-09-23 EP EP21873431.7A patent/EP4216978A4/en active Pending
- 2021-09-23 CN CN202180070652.0A patent/CN116457466A/zh active Pending
- 2021-09-23 US US18/027,250 patent/US20240025953A1/en active Pending
- 2021-09-23 JP JP2023518378A patent/JP2023542950A/ja active Pending
- 2021-09-23 CA CA3192936A patent/CA3192936A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022508182A5 (enExample) | ||
| IL299325B2 (en) | Acid-alpha glucosidase variants and uses thereof | |
| JP2022541070A5 (enExample) | ||
| JP2009526067A5 (enExample) | ||
| JP2021534814A5 (enExample) | ||
| US20190070271A1 (en) | Factor ix gene therapy | |
| JP2021512649A5 (enExample) | ||
| JP2023515072A5 (enExample) | ||
| JP2019511570A5 (enExample) | ||
| RU2018116076A (ru) | Модифицированные гены атаксии фридрейха и векторы для генной терапии | |
| JP2018500311A5 (enExample) | ||
| JP2022531809A5 (enExample) | ||
| JP2023534037A5 (enExample) | ||
| JP2024543918A5 (enExample) | ||
| JP2023542950A5 (enExample) | ||
| JP2022551744A5 (enExample) | ||
| JP2023524414A5 (enExample) | ||
| IL292264B2 (en) | aav transfer cassette | |
| JP2023509443A5 (enExample) | ||
| JP2022533448A5 (enExample) | ||
| JP2023065516A5 (enExample) | ||
| JP2021520811A5 (enExample) | ||
| JP2021527087A5 (enExample) | ||
| JP2023529371A5 (enExample) | ||
| JP2023520927A5 (enExample) |